Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 303

1.

Evaluating the Measurement Properties of the Self-Assessment of Treatment Version II, Follow-Up Version, in Patients with Painful Diabetic Peripheral Neuropathy.

van Nooten F, Trundell D, Staniewska D, Chen J, Davies EW, Revicki DA.

Pain Res Treat. 2017;2017:6080648. doi: 10.1155/2017/6080648. Epub 2017 Jan 16.

2.

Standards for Clinical Trials in Male and Female Sexual Dysfunction: III. Unique Aspects of Clinical Trials in Male Sexual Dysfunction.

Fisher WA, Gruenwald I, Jannini EA, Lev-Sagie A, Lowenstein L, Pyke RE, Reisman Y, Revicki DA, Rubio-Aurioles E.

J Sex Med. 2017 Jan;14(1):3-18. doi: 10.1016/j.jsxm.2016.08.016.

PMID:
28065358
3.

Standards for Clinical Trials in Male and Female Sexual Dysfunction: IV. Unique Aspects of Clinical Trials in Female Sexual Dysfunction.

Fisher WA, Gruenwald I, Jannini EA, Lev-Sagie A, Lowenstein L, Pyke RE, Reisman Y, Revicki DA, Rubio-Aurioles E.

J Sex Med. 2017 Jan;14(1):19-26. doi: 10.1016/j.jsxm.2016.09.022.

PMID:
28065357
4.

Editorial Comment: "Quantifying Barriers to Improvement of Treatment Satisfaction in Men With Erectile Dysfunction: Use of Person-Item Maps".

Revicki DA.

J Sex Med. 2017 Jan;14(1):160-161. doi: 10.1016/j.jsxm.2016.11.313. No abstract available.

PMID:
28065348
5.

Standards for Clinical Trials in Male and Female Sexual Dysfunction: II. Patient-Reported Outcome Measures.

Fisher WA, Gruenwald I, Jannini EA, Lev-Sagie A, Lowenstein L, Pyke RE, Reisman Y, Revicki DA, Rubio-Aurioles E.

J Sex Med. 2016 Dec;13(12):1818-1827. doi: 10.1016/j.jsxm.2016.08.015.

PMID:
27914562
6.

Standards for Clinical Trials in Male and Female Sexual Dysfunction: I. Phase I to Phase IV Clinical Trial Design.

Fisher WA, Gruenwald I, Jannini EA, Lev-Sagie A, Lowenstein L, Pyke RE, Reisman Y, Revicki DA, Rubio-Aurioles E.

J Sex Med. 2016 Dec;13(12):1805-1817. doi: 10.1016/j.jsxm.2016.09.021.

PMID:
27914561
7.

Development of the Hypogonadism Impact of Symptoms Questionnaire Short Form: Qualitative Research.

Gelhorn HL, Bodhani AR, Wahala LS, Sexton C, Landrian A, Miller MG, Derogatis L, Dobs A, Revicki DA.

J Sex Med. 2016 Nov;13(11):1729-1736. doi: 10.1016/j.jsxm.2016.09.007. Epub 2016 Oct 4.

8.

Psychometric Evaluation of the Hypogonadism Impact of Symptoms Questionnaire.

Gelhorn HL, Dashiell-Aje E, Miller MG, DeRogatis LR, Dobs A, Seftel AD, Althof SE, Brod M, Revicki DA.

J Sex Med. 2016 Nov;13(11):1737-1749. doi: 10.1016/j.jsxm.2016.09.006. Epub 2016 Sep 28.

9.

A PROMIS Measure of Neuropathic Pain Quality.

Askew RL, Cook KF, Keefe FJ, Nowinski CJ, Cella D, Revicki DA, Morgan DeWitt EM, Michaud K, Trence DL, Amtmann D.

Value Health. 2016 Jul-Aug;19(5):623-30. doi: 10.1016/j.jval.2016.02.009. Epub 2016 Apr 6.

PMID:
27565279
10.

Using Linear Equating to Map PROMIS(®) Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3.

Hays RD, Revicki DA, Feeny D, Fayers P, Spritzer KL, Cella D.

Pharmacoeconomics. 2016 Oct;34(10):1015-22. doi: 10.1007/s40273-016-0408-x.

11.

Evidence from diverse clinical populations supported clinical validity of PROMIS pain interference and pain behavior.

Askew RL, Cook KF, Revicki DA, Cella D, Amtmann D.

J Clin Epidemiol. 2016 May;73:103-11. doi: 10.1016/j.jclinepi.2015.08.035. Epub 2016 Feb 27.

PMID:
26931296
12.

Introduction to special section on patient-reported outcomes in nonstandard settings.

Schwartz CE, Revicki DA.

Qual Life Res. 2016 Mar;25(3):493-5. doi: 10.1007/s11136-016-1228-3. Epub 2016 Jan 23. No abstract available.

PMID:
26803828
13.

Content validity of the Sheehan Irritability Scale in patients with major depressive disorder.

Mannix S, Hassan M, Tummala R, Locklear JC, Revicki DA, Khan S, Dunbar GC, Eriksson H, Sheehan DV.

Int Clin Psychopharmacol. 2016 Mar;31(2):110-7. doi: 10.1097/YIC.0000000000000113.

PMID:
26655731
14.

Adolescent body weight and health-related quality of life rated by adolescents and parents: the issue of measurement bias.

Gandhi PK, Revicki DA, Huang IC.

BMC Public Health. 2015 Nov 30;15:1192. doi: 10.1186/s12889-015-2533-4.

15.

Assessing the Reliability and Validity of the Sheehan Irritability Scale in Patients With Major Depressive Disorder.

Khan SA, Revicki DA, Hassan M, Locklear JC, Friedman LA, Mannix S, Tummala R, Dunbar GC, Eriksson H, Sheehan DV.

J Clin Psychiatry. 2016 Aug;77(8):1080-6. doi: 10.4088/JCP.14m09719.

PMID:
26579723
16.

Scoring and Responsiveness of the Self-Assessment of Treatment Version Ii Questionnaire in Patients with Painful Diabetic Peripheral Neuropathy.

van Nooten FE, Trundell D, Staniewska D, Revicki DA.

Value Health. 2015 Nov;18(7):A706-7. doi: 10.1016/j.jval.2015.09.2654. Epub 2015 Oct 20. No abstract available.

17.

Content Validity of the Hypogonadism Impact of Symptoms Questionnaire (HIS-Q): A Patient-Reported Outcome Measure to Evaluate Symptoms of Hypogonadism.

Gelhorn HL, Vernon MK, Stewart KD, Miller MG, Brod M, Althof SE, DeRogatis LR, Dobs A, Seftel AD, Revicki DA.

Patient. 2016 Apr;9(2):181-90. doi: 10.1007/s40271-015-0138-8.

PMID:
26334870
18.

The PROMIS of QALYs.

Hanmer J, Feeny D, Fischhoff B, Hays RD, Hess R, Pilkonis PA, Revicki DA, Roberts MS, Tsevat J, Yu L.

Health Qual Life Outcomes. 2015 Aug 11;13:122. doi: 10.1186/s12955-015-0321-6.

19.

Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic Arthritis.

Wilson HD, Mutebi A, Revicki DA, Mease PJ, Genovese MC, Erondu N, Nirula A, Yuan FJ, Viswanathan HN.

Arthritis Care Res (Hoboken). 2015 Dec;67(12):1750-6. doi: 10.1002/acr.22653.

20.

Establishing a Common Metric for Physical Function: Linking the HAQ-DI and SF-36 PF Subscale to PROMIS(®) Physical Function.

Schalet BD, Revicki DA, Cook KF, Krishnan E, Fries JF, Cella D.

J Gen Intern Med. 2015 Oct;30(10):1517-23. doi: 10.1007/s11606-015-3360-0.

Supplemental Content

Loading ...
Support Center